Cardinal Health price target raised to $255 from $245 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cardinal Health (CAH) to $255 from $245 and keeps an Overweight rating on the shares. The risk reward for Cardinal Health has been updated following the company’s “strong” Q2 results, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
Disclaimer & DisclosureReport an Issue
- Cardinal Health price target raised to $252 from $250 at Baird
- Cardinal Health price target raised to $260 from $250 at UBS
- Cardinal Health price target raised to $260 from $250 at Evercore ISI
- Cardinal Health price target raised to $235 from $222 at Mizuho
- Cardinal Health’s Earnings Call Highlights Broad-Based Upswing
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.